| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Cardiovascular System | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Cardiovascular System | ||
phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Cardiovascular System |
Recent Updates
Recently added Catalysts
Longeveron Inc.$0.68
+0.01 (+0.77%)
C 42Pipeline Score Richly Valued Biotech · Clinical
Market Cap
25.57 M
EPS
-1.16
P/E Ratio
-
Value Trade
259.49 K
SEC Financials
Q1 2026Dilution Risk
40%Revenue
398.00 K
R&D Expenses
2.32 M
Operating CF
-4.37 M
Total Assets
21.21 M
Total Liabilities
5.18 M
Equity
16.03 M
D/E Ratio
12,345
19.75 %
Week
-18.79 %
1 Month
46.46 %
3 Month
36.7 %
6 Month
-98.63 %
5 Year
-99.18 %
All Time
Cash Data
Cash Position
15.76 M
Monthly Burn
1.46 M
Runway
9.1 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
111.44 K
52 Week Range
0.48 - 1.80
% held by Insiders
17.57 %
% held by Institutions
11.33 %
Enterprise Value
10.56 M
Total Shares
30.16 M
Short %
5.74 %
Float Shares
27.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Longeveron Inc.
376Total events
7Upcoming
73Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
2027
T1BLA Submission
BLA submission for HLHS anticipated in 2027 if ELPIS II results demonstrate sufficient efficacy
TBD
T2PRV Granted
Potential future receipt and sale of Rare Pediatric Disease PRV from FDA for laromestrocel in HLHS
TBD
T1Partnership / License
Anticipates entering licensing or partnering agreements for stem cell therapy for female sexual dysfunction
Event history 369
Q3 2026
◆Topline ReadoutlaromestrocelClinical Data
Top-line results from Phase 2b trial of laromestrocel in HLHS
Hypoplastic Left Heart Syndrome (HLHS)source ↗
Q3 2026
◆Timing GuidancelaromestrocelPresentation
Anticipated pivotal Phase 2b ELPIS II topline data readout in 3Q26
Hypoplastic Left Heart Syndrome (HLHS)source ↗
Jul 2026
◆Topline ReadoutlaromestorcelClinical Data
Top-line data expected approximately 13 months from June 2025
hypoplastic left heart syndrome (HLHS)source ↗
Jun 24, 2026
◆Oral PresentationlaromestrocelPresentation
Corporate presentation at BIO International Convention 2026
Jun 22, 2026
Jun 4, 2026
▲Enrollment CompletelaromestrocelTrial
Completed enrollment for Phase 2b ELPIS II trial in HLHS
Hypoplastic Left Heart Syndromesource ↗
May 13, 2026
May 11, 2026
▲DSMB ReviewlaromestrocelTrial
DMC positive review and recommendation to complete Phase 2b trial
hypoplastic left heart syndrome (HLHS)source ↗
Apr 8, 2026
▲Patent GrantedIP / Competition
China patent granted for potency assay methods for assessing human MSCs
Apr 2026
◆FDA Feedback ReceivedlaromestrocelFDA Meeting
FDA meeting summary received in late April 2026
hypoplastic left heart syndrome (HLHS)source ↗
Drug Pipeline Intelligence
C42
Pipeline Score $4M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.1x
rNPV / MCap Top 61%
Micro Cap (rank 356 of 911)
Percentile RankLongeveron Inc. carries a moderate pipeline score (42/100), with $476M risk-adjusted pipeline value, led by Longeveron Mesenchymal Stem Cells in Aging Frailty (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Longeveron Mesenchymal Stem Cells Monoclonal antibody | Aging Frailty | Phase 2 | NCT02982915 | 21% | $223M | COMPLETED | 212 | - | - | Sep 1, 2022 | - | Nov 4, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
laromestrocel Fast TrackRMATOrphan+1 | Alzheimer’s disease, Aging-related Frailty, Hypoplastic Left Heart Syndrome | Phase 1/2 | 2026-06-04 | positive initial results across 5 clinical trials in 3 indications Read More | Longeveron to Present at BIO International Convention 2026 | |
laromestrocel Fast TrackRMATOrphan+1 | Alzheimer’s disease, Aging-related Frailty, Hypoplastic Left Heart Syndrome | Phase 1/2 | 2026-06-04 | positive initial results across 5 clinical trials in 3 indications Read More | Longeveron to Present at BIO International Convention 2026 | |
laromestrocel Fast TrackRMATOrphan+1 | Alzheimer’s disease, Aging-related Frailty, Hypoplastic Left Heart Syndrome | Phase 1/2 | 2026-06-04 | positive initial results across 5 clinical trials in 3 indications Read More | Longeveron to Present at BIO International Convention 2026 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LGVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LGVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LGVNLongeveron® Appoints Marie Washburn as Chief Financial Officer
Longeveron Inc. has appointed Marie Washburn as Chief Financial Officer, effective July 13, 2026. Washburn, who has over 20 years of experience in the pharmaceutical and biotech sectors, previously served as Vice President and Corporate Controller at Longeveron. The company is focused on delivering results from its Phase 2b clinical trial for laromestrocel, a stem cell therapy for Hypoplastic Left Heart Syndrome, expected in Q3 2026.
Read more →LGVNLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron Inc. has received Small or Medium-sized Enterprise (SME) status from the European Medicines Agency (EMA). This designation provides the company with significant benefits, including access to scientific advice and reduced fees, which can enhance the chances of regulatory approval for its therapies. The SME program aims to support smaller companies in navigating the drug development process more effectively.
Read more →LGVNLongeveron to Present at BIO International Convention 2026
Longeveron Inc. will present at the BIO International Convention 2026, showcasing data on their stem cell therapy, laromestrocel. The company aims to establish partnerships for treating conditions like Hypoplastic Left Heart Syndrome and Alzheimer’s disease. They have reported positive results from clinical trials and anticipate further data from the Phase 2b ELPIS II trial in August 2026.
Read more →LGVNLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Priorities
Longeveron Inc. has outlined its corporate strategy and key priorities for 2026 in a letter to stockholders. The company is focusing on its stem cell therapy, laromestrocel, and is preparing for significant milestones, including data from its Phase 2b clinical trial in Hypoplastic Left Heart Syndrome. Longeveron aims to enhance stockholder value through strategic partnerships and a capital-efficient model.
Read more →LGVNLongeveron Announces 2026 First Quarter Financial Results and Provides Business Update
Longeveron Inc. reported its first quarter financial results for 2026, highlighting a strategic repositioning to enhance shareholder value. The company anticipates top-line results from its Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome by August 2026. Additionally, Longeveron successfully closed a $30 million private placement to support its operations and development programs.
Read more →LGVNLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron announced that the independent Data Monitoring Committee has completed its review of the Phase 2b clinical trial (ELPIS II) for laromestrocel, an adjunct therapy for hypoplastic left heart syndrome (HLHS). The DMC found no safety concerns and recommended continuing the trial as designed. Top-line results are expected in August 2026.
Read more →LGVNLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced a constructive Type C meeting with the FDA regarding its ELPIS II Phase 2b trial for laromestrocel in treating hypoplastic left heart syndrome (HLHS). The FDA acknowledged the significant unmet need for effective therapies but raised concerns about the trial's primary endpoint. Despite this, Longeveron is optimistic about future discussions and potential regulatory pathways following the trial's results, expected in August 2026.
Read more →LGVNLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
Longeveron Inc. will report its first quarter financial results for 2026 and provide a business update on May 13, 2026. The company, focused on cellular therapies for critical health conditions, will host a conference call at 4:30 p.m. ET. The event will be accessible via webcast, with an archived replay available afterward.
Read more →LGVNLongeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Longeveron Inc. has announced the issuance of a patent by the China National Intellectual Property Administration for potency assay methods related to human mesenchymal stem cells (MSCs). This patent adds to the company's strong global patent portfolio, now totaling 52 patents, and secures rights until 2041. Longeveron's lead product, laromestrocel, is currently in clinical trials for various conditions, including hypoplastic left heart syndrome, with promising designations from the FDA that may facilitate its path to regulatory approval.
Read more →LGVN▲ +8.1%on this news
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
Longeveron Inc. has reported its financial results for the year ending December 31, 2025, and provided an update on its business developments. The company is focusing on its pivotal Phase 2b clinical trial, ELPIS II, which evaluates laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS), with results expected in Q3 2026. Longeveron has successfully closed a $30 million private placement, enabling further advancements in its clinical programs. The company aims to leverage partnerships to optimize capital use and accelerate time-to-market for its therapies addressing serious pediatric and aging-related conditions.
Read more →LGVN▲ +20.3%on this newsshared move
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
Longeveron Inc. will report its 2025 full-year financial results on March 17, 2026, after market close. The company will also host a conference call at 4:30 p.m. ET to provide a business update. Longeveron is focused on developing cellular therapies for rare pediatric and aging-related conditions, with its lead product, laromestrocel, showing promise in various indications.
Read more →LGVN▼ -8.8%on this newsshared move
Longeveron Announces Closing of Private Placement of up to $30 Million
Longeveron Inc. announced the successful closing of a private placement totaling up to $30 million, primarily aimed at supporting its clinical development of laromestrocel for hypoplastic left heart syndrome. The initial tranche has already secured $15 million, extending the company's cash runway through the fourth quarter of 2026 and beyond an anticipated pivotal clinical trial's data readout. The placement was led by Coastlands Capital and included participation from other healthcare-focused funds. Proceeds will facilitate ongoing clinical and regulatory development along with other operational needs.
Read more →LGVN▲ +68.3%on this news· ran to +84% by day 3shared move
Longeveron Announces Private Placement of up to $30 Million
Longeveron Inc. announced the completion of a private placement which could bring in up to $30 million. The initial closing will provide $15 million to support the company's operations and is aimed at extending its financial runway through 2026, specifically in support of its ELPIS II clinical trial in Hypoplastic Left Heart Syndrome (HLHS). This funding may include an additional $15 million contingent on achieving specific milestone conditions. The placement is led by Coastlands Capital with significant participation from other institutional investors.
Read more →LGVN▲ +68.3%on this news· ran to +84% by day 3shared move
Longeveron Announces Private Placement of up to $15 Million $15 million upfront with a milestone-driven potential additional $15 million related to the Company's anticipated pivotal clinical trial in Hypoplastic Left Hea
Longeveron Inc. announced a private placement to raise up to $30 million, with an initial $15 million expected to support its ongoing clinical trials, including the pivotal Phase 2b ELPIS II trial for Hypoplastic Left Heart Syndrome (HLHS). The financing, arranged with institutional investors, involves the issuance of common and preferred stock. Furthermore, the company may receive an additional $15 million contingent on achieving specific trial milestones. Proceeds will also support regulatory development and enhance working capital.
Read more →LGVN▲ +5.7%on this news
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
Longeveron Inc. announced positive results from its Phase 2b clinical trial of laromestrocel, a stem cell therapy aimed at improving the condition of patients with age-related frailty. The trial demonstrated significant improvements in physical functioning after nine months compared to a placebo. The findings suggest a promising approach for managing frailty in vulnerable populations.
Read more →LGVNLongeveron Appoints Stephen H. Willard as Chief Executive Officer Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an
Longeveron Inc. has appointed Stephen H. Willard as its new Chief Executive Officer, effective February 11, 2026, succeeding Than Powell. Mr. Willard brings over 30 years of leadership experience from various biotechnology firms and aims to enhance Longeveron's operations, especially as the company develops pivotal therapies for life-threatening diseases. The company is set to release important clinical trial results for its lead product, laromestrocel, later this year, which may support future regulatory submissions. Powell will assist in the transition while continuing his role in business development.
Read more →LGVN▼ -5.3%on this news
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Longeveron Inc. supports the passage of the Mikaela Naylon Give Kids a Chance Act, which reauthorizes the Rare Pediatric Disease Priority Review Voucher Program. This program incentivizes the development of treatments for rare pediatric diseases. Longeveron is advancing its clinical trial for laromestrocel, aimed at improving survival rates for children with Hypoplastic Left Heart Syndrome (HLHS). Positive trial results could lead to a Biological License Application by 2026.
Read more →LGVNLongeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Longeveron Inc. has been granted a patent by the Japan Patent Office for potency assay methods related to human mesenchymal stem cells. This patent, valid until April 2041, enhances the company's intellectual property portfolio, which now includes 33 patents. Longeveron is currently conducting a pivotal Phase 2b trial for its product laromestrocel in treating hypoplastic left heart syndrome, with results expected in Q3 2026.
Read more →LGVN▼ -6.7%on this newsshared move
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced that the FDA has granted a Type C meeting to discuss the pivotal Phase 2 clinical trial, ELPIS II, for their stem cell therapy, laromestrocel, aimed at treating Hypoplastic Left Heart Syndrome (HLHS). This meeting, scheduled for late March, will focus on aligning clinical efficacy data endpoints to support a Biologics Licensing Application. The trial has enrolled 40 pediatric patients and is conducted in collaboration with the NHLBI.
Read more →LGVNLongeveron, Selected as a StartUp Health Alzheimer’s Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026
Longeveron Inc. has been chosen as a StartUp Health Alzheimer’s Disease Moonshot company and will participate in the Apollo House during JPM Healthcare Week in January 2026. This initiative aims to accelerate breakthroughs in Alzheimer’s and related diseases, supported by notable organizations. Longeveron will also engage with investors and partners during this event.
Read more →LGVN▲ +7.8%on this news
Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy
Longeveron Inc. has been granted a U.S. patent for its proprietary stem cell therapy aimed at treating female sexual dysfunction. The patent, which provides rights until 2038, highlights the company's commitment to addressing this common yet under-researched issue. Longeveron plans to explore licensing or partnerships for the commercialization of this therapy, which could significantly improve the quality of life for affected women.
Read more →LGVNLongeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
Longeveron Inc. has been granted a Canadian patent for its proprietary mesenchymal stem cell therapy, laromestrocel, aimed at treating aging-related frailty and non-ischemic dilated cardiomyopathy (NIDCM). The patent, valid until 2037, underscores the company's commitment to addressing chronic conditions associated with aging. Previous studies have shown potential benefits of laromestrocel in improving physical functioning in frail patients.
Read more →LGVNLongeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
Longeveron Inc. has announced that its Chief Science Officer, Dr. Joshua Hare, and Chief Medical Officer, Dr. Nataliya Agafonova, will participate as speakers at the upcoming Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., from December 8-10, 2025. They will engage in panel discussions focused on cell therapy and its implications in heart failure trials. This highlights Longeveron's commitment to contributing to significant advancements in cardiovascular research and showcases the potential of their lead product, laromestrocel, which targets several critical conditions.
Read more →LGVN▼ -5.1%on this newsshared move
Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer’s Disease Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Longeveron Inc. presented data on laromestrocel, a stem cell therapy, at the Clinical Trials on Alzheimer's Disease Conference. The Phase 2 CLEAR-MIND trial demonstrated that laromestrocel reduced neuroinflammation in Alzheimer's patients, particularly in the hippocampus, and correlated with clinical improvements. The findings reinforce its mechanism of action and support the ongoing development of laromestrocel for treating mild Alzheimer's disease. Additional positive results included improvements in cognitive function and quality of life.
Read more →LGVNLongeveron Laromestrocel Data in Alzheimer’s Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025)
Longeveron Inc. has announced that its research on laromestrocel, focusing on reducing brain neuroinflammation in mild Alzheimer's disease, has been selected for a poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference (CTAD 2025). The presentation is scheduled for December 1-4, 2025, in San Diego, California. CEO Joshua Hare expressed optimism about the potential insights the data could provide for developing new therapy options for Alzheimer's. Laromestrocel is derived from mesenchymal stem cells and is being investigated for multiple therapeutic applications.
Read more →LGVNLongeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Longeveron Inc. has received a U.S. patent for its method of treating aging-related frailty using its proprietary Mesenchymal Stem Cells. The patent, effective until 2038, supports the company's ongoing development of laromestrocel, a stem cell therapy aimed at improving healthspan in older individuals. The therapy targets symptoms associated with frailty and inflammation, with previous studies indicating positive outcomes.
Read more →LGVNLongeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
Longeveron Inc. reported its third quarter 2025 financial results and provided a business update. The company is advancing its laromestrocel therapy through a pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome, with results expected in Q3 2026. Positive outcomes could lead to the company's first BLA filing with the FDA. Longeveron is also pursuing multiple indications for its stem cell therapy.
Read more →LGVNLongeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Longeveron Inc. will report its third quarter 2025 financial results on November 4, 2025, after market close. The company will also host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Longeveron focuses on developing cellular therapies for rare pediatric and chronic aging-related conditions.
Read more →LGVNLongeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Longeveron Inc. announced that Dr. Joshua Hare discussed their stem cell therapy, laromestrocel, for hypoplastic left heart syndrome (HLHS) on NPR's BioTech Nation. The ongoing Phase 2b trial, ELPIS II, aims to evaluate laromestrocel's efficacy, building on promising results from the ELPIS I trial. The FDA has granted several designations to support the therapy's development.
Read more →LGVNLongeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. The company aims to engage with investors through one-on-one meetings. Longeveron is focused on developing cellular therapies, particularly laromestrocel, for various serious medical conditions, supported by several FDA designations.
Read more →LGVNGeorge Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Longeveron Inc. has elected Dr. George Paletta, Jr. to its Board of Directors. Dr. Paletta, a renowned orthopedic surgeon and entrepreneur, is expected to enhance the company's efforts in developing stem cell therapies for serious pediatric and aging-related conditions. Longeveron is currently advancing its clinical trials, with significant data anticipated in the near future.
Read more →LGVNLongeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Longeveron Inc. will attend the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa from October 6-8, 2025. The company aims to discuss potential partnerships for its stem cell therapy program targeting Alzheimer's disease. Laromestrocel, their lead candidate, has shown promising results in clinical trials, indicating its potential in treating mild Alzheimer's.
Read more →LGVN▼ -8.3%on this news
Longeveron® Announces Key Leadership Updates
Longeveron Inc. has announced significant leadership changes, appointing Than Powell as interim CEO and Dr. Joshua Hare as Executive Chairman. The company is advancing its clinical programs, particularly laromestrocel, which has shown promising results in trials. With a robust pipeline and full enrollment in a pivotal trial, Longeveron aims to enhance its impact in regenerative medicine.
Read more →LGVNLongeveron Announces Key Leadership Updates Than Powell, Chief Business Officer and head of business development, appointed Interim CEO Dr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman
Longeveron announced key leadership updates, with Than Powell appointed as interim CEO succeeding Wa'el Hashad. Dr. Joshua Hare, the company's founder, has been named Executive Chairman. Both leaders possess significant industry experience and have shown a commitment to advancing Longeveron's pipeline, which includes the stem cell therapy laromestrocel. The company looks forward to embarking on a national search for a permanent CEO while they continue to progress with their clinical trials.
Read more →LGVNLongeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Longeveron Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company focuses on developing cellular therapies for rare pediatric and aging-related conditions. Their lead product, laromestrocel, has received several FDA designations, highlighting its potential in treating critical health issues.
Read more →LGVN▲ +26.4%on this news
Longeveron Announces Second Quarter 2025 Financial Results and Provides Business Update Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment fo
Longeveron Inc. (NASDAQ: LGVN) reported its second quarter 2025 financial results, highlighting full enrollment in its pivotal Phase 2b clinical trial for laromestrocel, a potential treatment for hypoplastic left heart syndrome (HLHS). The company announced positive outcomes from five clinical trials across various indications and ongoing positive engagements with the FDA regarding its regulatory pathways. To position for a potential BLA filing in late 2026, Longeveron aims to advance its BLA readiness within this year. The financial analysis shows a decrease in cash reserves compared to the previous year, indicating a potential need for additional funding.
Read more →LGVNLongeveron Announces Closing Of Up To $17.5 Million Public Offering
Longeveron Inc. has announced the successful closing of a public offering involving nearly 5.9 million shares of its Class A common stock, raising approximately $5.0 million. The total possible proceeds could reach $17.5 million if short-term warrants are fully exercised. The company plans to use the net proceeds to advance its ongoing clinical and regulatory efforts for laromestrocel, which targets rare pediatric and aging-related conditions. This offering highlights Longeveron's commitment to developing innovative therapies despite the uncertainty surrounding the exercise of the warrants.
Read more →LGVN▼ -46.6%on this newsshared move
Longeveron Announces Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI
Longeveron Inc. has announced a public offering aimed at raising up to $17.5 million, which includes $5 million upfront. The offering consists of shares of Class A common stock along with short-term warrants for additional shares. The funds are expected to enhance the company's ongoing clinical and regulatory development efforts for its lead therapy, laromestrocel, targeting several conditions such as HLHS and Alzheimer's disease. Although insider participation indicates confidence, uncertainties regarding the exercise of warrants and market conditions pose potential risks.
Read more →LGVN▼ -9.4%on this news· ran to -60% by day 3shared move
Longeveron to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Longeveron Inc. (NASDAQ: LGVN) has announced that it will report its second quarter 2025 financial results on August 13, 2025, followed by a conference call at 4:30 p.m. ET. The biotechnology company, which specializes in regenerative medicine, aims to provide a business update during this session. Longeveron is developing cellular therapies for various conditions including hypoplastic left heart syndrome and Alzheimer's disease, and has received significant FDA designations for its products.
Read more →LGVN▲ +10.5%on this news
Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Longeveron has licensed a new cardiac selective induced pluripotent stem cell technology from the University of Miami, protected under US Patent 12,168,028 B2. This licensed technology allows for the derivation of GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells, positioning Longeveron to enhance its existing repertoire of stem cell therapies. The company believes this advancement offers vast potential for addressing various heart diseases, particularly in pediatric and rare disease contexts. This strategic move also aims to mitigate the risks associated with existing stem cell treatments and promote safer cardiac muscle cell differentiation.
Read more →LGVN▲ +28.7%on this news
Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) Accepted IND application allows for dev
Longeveron Inc. has announced the FDA's approval of its IND application for laromestrocel, a stem cell therapy intended to treat pediatric dilated cardiomyopathy (DCM). This approval enables Longeveron to proceed directly to a Phase 2 pivotal registration study focused on this rare, life-threatening condition, which currently lacks effective treatments. With a high percentage of affected children facing severe outcomes, the development of laromestrocel reflects Longeveron's dedication to addressing significant medical needs in pediatric cardiovascular care.
Read more →LGVNLongeveron Appoints Than Powell as Chief Business Officer
Longeveron Inc. has appointed Than Powell as Chief Business Officer to oversee its partnering and international strategy efforts. Effective July 7, 2025, Powell will lead the company’s business strategy and focus on its Alzheimer's disease program and hypoplastic left heart syndrome (HLHS) initiative. Longeveron is nearing the top-line data from its pivotal Phase 2 trial for laromestorcel, which could enable the company to submit its first Biological License Application if results are favorable.
Read more →LGVN▲ +7.8%on this newsshared move
Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. has completed enrollment for its pivotal Phase 2b clinical trial, ELPIS II, evaluating laromestrocel for treating Hypoplastic Left Heart Syndrome (HLHS). Results are expected in the third quarter of 2026, contingent on positive outcomes that would support a Biological License Application submission. The FDA has awarded laromestrocel multiple designations, highlighting its potential in addressing significant unmet medical needs in pediatric patients affected by HLHS. The trial builds on earlier successes that demonstrated high transplant-free survival rates among treated patients.
Read more →LGVNLongeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16-17, 2025. CEO Wa'el Hashad will present a pre-recorded session available on June 16. The conference aims to highlight the company’s innovative cellular therapies for chronic aging-related conditions. Longeveron's investigational product, laromestrocel, is addressing significant unmet medical needs and has received multiple FDA designations, enhancing its potential in the market.
Read more →LGVNLongeveron to Attend BIO International Convention 2025
Longeveron Inc. (NASDAQ: LGVN) announced its attendance at the BIO International Convention from June 16-19, 2025, in Boston. The company will discuss potential partnerships for its Alzheimer’s disease stem cell therapy program. Notably, an FDA meeting confirmed plans for a pivotal Phase 2/3 trial of laromestrocel, expected to begin in the second half of 2026 if funding is secured. The therapy has shown promising results in earlier trials, making it a candidate for Federal approval.
Read more →LGVN▲ +9.7%on this news
Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Longeveron Inc. has been named a Top 40 Semifinalist in the XPRIZE Healthspan competition, receiving a $250,000 Milestone 1 Award. The competition aims to revolutionize human aging, with participants required to demonstrate feasible approaches to extending healthy life. Longeveron's stem cell therapy, laromestrocel, is being investigated for its potential in treating Alzheimer's disease and hypoplastic left heart syndrome, with positive initial results from several clinical trials. The company aims to advance to the Finals stage, where it could compete for a grand prize of up to $81 million.
Read more →LGVNLongeveron Announces First Quarter 2025 Financial Results and Provides Business Update Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indicatio
Longeveron Inc. has released its first quarter 2025 financial results, highlighting advancements in the development of laromestrocel for rare pediatric and neurodegenerative diseases. The company is focused on completing its pivotal Phase 2b clinical trial, ELPIS II, for hypoplastic left heart syndrome and preparing for a potential BLA filing in 2026. Additionally, they aim to utilize positive data to engage partners for expanding the therapeutic uses of laromestrocel, particularly in Alzheimer’s disease.
Read more →LGVNLongeveron to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Longeveron Inc. announced it will report its first quarter 2025 financial results on May 8, 2025, after the market closes. The company will also host a conference call at 4:30 p.m. ET on the same day. Longeveron specializes in regenerative medicine with a focus on its lead product laromestrocel for various chronic conditions. The company has received multiple FDA designations supporting its developmental efforts in numerous pipeline indications, including Alzheimer’s disease and hypoplastic left heart syndrome.
Read more →LGVNLongeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
Longeveron Inc. has shared a strategic update to shareholders, outlining its progress in developing laromestrocel, a stem cell therapy targeting Alzheimer's disease and Hypoplastic Left Heart Syndrome (HLHS). The company anticipates pivotal clinical trials and regulatory clarity from the FDA regarding its Biological License Application (BLA) submissions. Notably, laromestrocel's promising results in clinical studies, particularly for HLHS, have garnered attention, with expectations for significant advancements in 2025. The firm aims to establish its presence in global markets, enhancing its commercialization strategies further.
Read more →LGVNLongeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
Longeveron Inc. announced a positive outcome of a Type B meeting with the FDA, indicating support for its laromestrocel (Lomecel-BTM) as a potential Alzheimer’s treatment. The company plans to initiate a pivotal Phase 2/3 clinical trial in the second half of 2026, pending funding. The FDA has granted laromestrocel RMAT designation, which facilitates faster development and potential accelerated approval. Previous clinical trial results showed a favorable safety profile and signals of efficacy, providing optimism for future studies.
Read more →LGVN▲ +5.4%on this news· ran to +16% by day 1
Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
Longeveron Inc. announced the publication of results from the Phase 2a CLEAR MIND clinical trial for laromestrocel (Lomecel-B™), a potential cellular therapy for mild Alzheimer's disease. The trial indicated improvements in cognitive function, quality of life, and reduced brain volume loss in treated patients compared to placebo. Laromestrocel is the first cellular therapeutic candidate to receive FDA Regenerative Medicine Advanced Therapy designation for Alzheimer's, reflecting its promising safety and efficacy profile. The publication in Nature Medicine reinforces the potential of this treatment in addressing Alzheimer's disease.
Read more →LGVN▲ +5.3%on this news
Longeveron to Present at the 37th Annual Roth Conference
Longeveron Inc. (NASDAQ: LGVN) has announced its participation in the 37th Annual Roth Conference scheduled for March 17-18, 2025. The company will hold a fireside chat on March 18, which can be accessed via their website. Longeveron is known for its regenerative medicine products and is developing therapies aimed at treating various aging-related conditions. Their lead product, Lomecel-B™, has received several important FDA designations indicating its potential in clinical development.
Read more →LGVNLongeveron Announces Full-Year 2024 Financial Results and Provides Business Update Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B TM (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pedi
Longeveron Inc. has announced its financial results for the full year ending December 31, 2024, reporting advances in its pivotal Phase 2b clinical trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS). CEO Wa'el Hashad highlighted the potential for transformational milestones, including an upcoming meeting with the FDA regarding Alzheimer's disease. Lomecel-B has received several FDA designations, showing promise in multiple indications. The report notes an increase in cash reserves but also points to ongoing challenges regarding capital access and clinical trial success.
Read more →LGVNLongeveron to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
Longeveron Inc. announced it will report its full-year 2024 financial results and provide a business update on February 28, 2025, after U.S. market close. A conference call and webcast will follow at 4:30 p.m. ET. The company is known for its regenerative medicine efforts, specifically its investigational product Lomecel-B™, which has received several important FDA designations for its clinical programs targeting various serious conditions.
Read more →LGVN▼ -5.4%on this newsshared move
Longeveron Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Longeveron Inc. has announced that its cellular therapy Lomecel-B™ has received the International Non-proprietary Name laromestrocel from the World Health Organization. This marks a crucial step in the therapy's development and potential commercialization, which is being evaluated for Alzheimer’s disease and hypoplastic left heart syndrome. The therapy is recognized for its innovative application in regenerative medicine, bolstered by positive Phase 2a trial results and multiple FDA designations aimed at expediting its clinical pathway. The upcoming completion of enrollment for a Phase 2b trial is anticipated to further support its therapeutic potential.
Read more →LGVN▲ +6.4%on this newsshared move
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
Longeveron Inc. (NASDAQ: LGVN) will present at the Emerging Growth Virtual Conference on February 19, 2025. This participation showcases the company's commitment to highlighting its regenerative medicine innovations. Longeveron is focused on addressing chronic and aging-related conditions through its lead product, Lomecel-B™, which has secured several FDA designations. The webcast for the presentation will be accessible on the company's website and will be available for replay for 180 days post-conference.
Read more →LGVN▼ -7.3%on this news
Longeveron to Present at Biotech Showcase 2025
Longeveron Inc. announced that CEO Wa’el Hashad will present at the Biotech Showcase from January 13-15, 2025. The presentation is scheduled for January 14, 2025, from 4:00 to 4:30 p.m. PT. Longeveron is focused on developing regenerative medicines, particularly their lead product Lomecel-B™, which targets conditions such as Alzheimer’s disease and hypoplastic left heart syndrome.
Read more →LGVNLongeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Longeveron Inc. will participate in the Emerging Growth Virtual Conference on December 5, 2024. The company, which focuses on developing cellular therapies for serious aging-related conditions, is expected to present details on their lead product, Lomecel-B. This therapy has received multiple FDA designations, showcasing its potential significance in the field of regenerative medicine. A webcast of the event will be available for participants and can be accessed afterward for an extended period.
Read more →LGVN▲ +6%on this news
Longeveron Announces Third Quarter 2024 Financial Results and Provides Business Update Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B TM in rare pediatric disease HLHS has achieved more than 80% enrollment Posit
Longeveron Inc. (NASDAQ: LGVN) reported its third quarter 2024 financial results and indicated progress in clinical trials for its cellular therapy candidate, Lomecel-B. The company has successfully achieved over 80% enrollment in the ELPIS II clinical trial, which evaluates the treatment's efficacy for Hypoplastic Left Heart Syndrome (HLHS). Additionally, Longeveron received a positive indication from the FDA regarding a Biological License Application (BLA) for the trial. The Phase 2a data for Lomecel-B in mild Alzheimer's was also acknowledged at key medical conferences, reinforcing the potential impact of their research efforts.
Read more →LGVNLongeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Longeveron Inc. has appointed Devin Blass as Chief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls, effective December 2, 2024. This leadership change aims to strengthen the company's technology and manufacturing strategies as it progresses towards a potential Biological License Application submission for its lead therapy, Lomecel-B, in treating hypoplastic left heart syndrome. Mr. Blass joins with extensive experience in advanced therapies, indicating a strategic commitment to advancing regenerative medicine.
Read more →LGVN▲ +6.4%on this news
Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Longeveron Inc. (NASDAQ: LGVN) is scheduled to report its third quarter 2024 financial results on November 12, 2024, after the U.S. financial markets close. A conference call and webcast will follow at 4:30 p.m. ET, providing further insights into the company's activities. Longeveron, focused on regenerative medicine, is advancing therapies for conditions like Alzheimer’s Disease and hypoplastic left heart syndrome, with its product Lomecel-B™ having received multiple FDA designations.
Read more →LGVNLongeveron Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Longeveron Inc. presented promising data on Lomecel-B, a cellular therapy for mild Alzheimer's disease, at the Clinical Trials on Alzheimer's Disease Conference (CTAD24). The findings suggest Lomecel-B's ability to inhibit MMP14 may correlate with improved clinical and biomarker outcomes. Enhanced responses were observed in patients demonstrating higher MMP14 inhibitory activity, suggesting potential mechanisms for its therapeutic effects. The data draws on prior positive results from the Phase 2a CLEAR MIND trial, indicating the safety and efficacy of Lomecel-B in treating mild Alzheimer's.
Read more →LGVNLongeveron Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Longeveron Inc. reported positive long-term survival results for their treatment Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS) patients at the CHSS meeting. The study demonstrated a 100% transplant-free survival rate five years post-surgery, significantly outpacing historical data. The ongoing ELPIS II trial aims to further assess Lomecel-B™ in HLHS treatment. The findings highlight the potential of this cell-based therapy to address critical unmet needs in this patient population.
Read more →LGVN▲ +8.4%on this news· ran to +23% by day 3
Longeveron Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Longeveron Inc. has announced that its research on Lomecel-B will be featured as a late breaking poster presentation at the CTAD24 conference in Madrid, taking place from October 29 to November 1, 2024. The presentation, titled "Lomecel-B inhibition of MMP14 activity predicts Lomecel-B bioactivity in the treatment of mild Alzheimer's disease," aims to highlight the potential mechanisms of Lomecel-B in addressing Alzheimer's. The abstract will also appear in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease.
Read more →LGVNLongeveron Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Longeveron Inc. has announced that its study on long-term transplant-free survival data for Hypoplastic Left Heart Syndrome (HLHS) has been selected for oral presentation at the Congenital Heart Surgeons' Society 51st Annual Meeting. The presentation will showcase data from their ELPIS I follow-on study, which indicates improved survival rates with their cell-based therapy, Lomecel-B™. The company is also advancing to the ELPIS II Phase 2b clinical trial, potentially paving the way for a BLA submission if results are favorable.
Read more →LGVNLongeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
Longeveron Inc. (NASDAQ: LGVN) has announced that its CEO, Wa'el Hashad, will participate in a Fireside Chat during the UBS Virtual Organ Restoration and Cell Therapy Day on October 15, 2024. The event aims to showcase advancements in regenerative medicine, a key area for Longeveron, which is developing its lead product, Lomecel-B™, aimed at addressing serious medical conditions. Lomecel-B™ has received various important FDA designations, underscoring its promising future in clinical applications.
Read more →LGVNLongeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference scheduled for October 9, 2024, in New York City. CEO Wa'el Hashad will speak on a panel discussing emerging frontiers in neuroscience and will participate in one-on-one investor meetings. The company's lead product, Lomecel-B™, is being developed for conditions such as hypoplastic left heart syndrome and Alzheimer's disease, and has garnered significant FDA designations for its development programs.
Read more →LGVNLongeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
Longeveron Inc. will participate in the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa from October 7-9, 2024. The Company aims to explore partnership opportunities for its cellular therapy program targeting Alzheimer's disease, which has recently yielded positive results in clinical trials. Additionally, Longeveron will highlight its manufacturing capabilities at its GMP-compliant facility in Miami. The lead therapy candidate, Lomecel-B™, has received FDA designations affirming its potential in treating mild Alzheimer's disease.
Read more →LGVNLongeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. announced a positive Type C meeting with the U.S. FDA regarding its Lomecel-B™ therapy for hypoplastic left heart syndrome (HLHS). The FDA has aligned with the company on both primary and secondary endpoints for the ongoing Phase 2b clinical trial, ELPIS II, which could potentially support a Biological License Application (BLA) submission if the results are favorable. Previous trials have reported promising outcomes, significantly enhancing transplant-free survival rates among infants. The therapy has received several FDA designations, indicating strong regulatory support for its development.
Read more →LGVN▼ -6.2%on this news· ran to -19% by day 3
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Longeveron Inc. (NASDAQ: LGVN) will participate in the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024, in New York City. The company's presentation will take place on September 10, 2024, from 5:00 to 5:30 p.m. ET. Longeveron's lead product, Lomecel-B, is a regenerative medicine aimed at addressing chronic aging-related conditions and has received several important FDA designations for its development programs targeting conditions like Alzheimer’s disease and hypoplastic left heart syndrome.
Read more →LGVNLongeveron Announces Second Quarter 2024 Financial Results and Provides Business Update Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B TM in Alzheimer's disease presented in Featured Re
Longeveron Inc. announced its financial results for the second quarter of 2024, highlighting significant progress with its investigational cellular therapy candidate, Lomecel-B. The company received key FDA designations for Lomecel-B in treating mild Alzheimer's disease, supported by positive data from a recent clinical trial. Additionally, the ELPIS II Phase 2b trial for Hypoplastic Left Heart Syndrome has reached 70% enrollment. With raised capital, Longeveron is positioned to sustain its operations through the end of 2025.
Read more →LGVN▼ -8.3%on this news
Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
Longeveron Inc. (NASDAQ: LGVN) has announced its plans to report second quarter 2024 financial results and provide a business update on August 14, 2024. The company, known for developing regenerative therapies, will host a conference call at 4:30 p.m. ET on the same day. Their lead investigational product, Lomecel-B™, is currently in development for several serious conditions and has received important FDA designations to bolster its regulatory standing.
Read more →LGVNLongeveron Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC)
Longeveron presented positive results from the Phase 2a CLEAR MIND trial of Lomecel-B™ for mild Alzheimer’s Disease at the AAIC conference. The trial demonstrated significant improvements in cognitive functions, quality of life, and a reduction in brain volume loss among treated patients. Safety data showed no incidence of severe adverse effects. With FDA designations already in place, Longeveron aims to further explore the therapeutic potential of Lomecel-B™.
Read more →LGVNLongeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. has completed a registered direct offering that raised approximately $9.0 million through the sale of 2,236,026 shares of its Class A common stock at $4.025 per share. In conjunction with this offering, the company also issued unregistered warrants to purchase an equal number of shares. The raised funds will be utilized for clinical and regulatory development of Lomecel-B™, an investigational therapy targeting serious diseases such as hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, along with other general corporate purposes.
Read more →LGVN▼ -16.7%on this newsshared move
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI
Longeveron Inc. has announced the issuance and sale of approximately 2,236,026 shares of its Class A common stock at a price of $4.025 per share, amounting to an expected total of $9.0 million from the offering. The proceeds will be utilized for ongoing clinical development and regulatory processes for its lead product, Lomecel-B, which targets significant health issues like HLHS and Alzheimer's disease. H.C. Wainwright & Co. will act as the placement agent, with the offering anticipated to close around July 19, 2024. The company has experienced various FDA designations aimed at expediting its therapies.
Read more →LGVN▲ +10.8%on this newsshared move
Longeveron Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
Longeveron Inc. has announced that the U.S. FDA has granted Fast Track designation for its investigational therapy Lomecel-B™ aimed at treating mild Alzheimer's disease. This designation is significant as it facilitates expedited clinical development and regulatory review, following a previous Regenerative Medicine Advanced Therapy designation. The company plans to present positive data from its Phase 2a CLEAR MIND trial at the upcoming Alzheimer's Association International Conference, showcasing the therapy's potential impact on patients and families affected by Alzheimer's disease.
Read more →LGVN▲ +58.5%on this news
Longeveron Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
Longeveron Inc. announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation for their investigational therapy Lomecel-B™ to treat mild Alzheimer's Disease. Following positive results from the CLEAR MIND Phase 2a clinical trial, which showed significant improvements over placebo, Lomecel-B™ has emerged as a promising therapeutic option amid limited existing treatments. This designation is a significant milestone for Longeveron, allowing for enhanced dialogue with the FDA to advance its development pathway. The company's program also holds various other FDA designations, validating its innovative approach to regenerative medicine.
Read more →LGVN▲ +58.5%on this news
Longeveron Announces U.S. FDA Grants Lomecel-B TM Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease - Lomecel-B TM appears to be the first cellular therapeutic candid
Longeveron Inc. announced that the U.S. FDA has granted its therapy, Lomecel-BTM, the Regenerative Medicine Advanced Therapy (RMAT) designation for treating mild Alzheimer's Disease. This designation positions Lomecel-BTM as the first cellular therapeutic candidate to be recognized for this application. Data from the CLEAR MIND Phase 2a clinical trial indicated significant efficacy in slowing disease progression compared to a placebo. Longeveron is set to present full clinical trial results at the upcoming Alzheimer's Association International Conference.
Read more →LGVN▲ +38.6%on this news· ran to +120% by day 1shared move
Longeveron Announces U.S. FDA Grants Fast Track Designation for Lomecel-B TM for the Treatment of Mild Alzheimer's Disease - FDA designation enables expedited clinical development and regulatory review timelines for Lome
Longeveron has received Fast Track designation from the U.S. FDA for Lomecel-B, a therapy targeting mild Alzheimer's Disease. This designation is a significant milestone, facilitating faster clinical development and regulatory review. Lomecel-B has already obtained a Regenerative Medicine Advanced Therapy (RMAT) designation and has shown promising Phase 2a trial results. The company will present full results of the trial at the upcoming Alzheimer's Association International Conference in July 2024.
Read more →LGVN▼ -7.5%on this news· ran to -20% by day 3
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
Longeveron Inc. announced the completion of a warrant exercise that generated approximately $4.4 million in gross proceeds. The exercise involves 1,697,891 shares of Class A common stock at an exercise price of $2.35 each. Proceeds from this transaction will support the ongoing development of their cell therapy product Lomecel-B™ aimed at treating conditions such as hypoplastic left heart syndrome and Alzheimer's disease. Additionally, new warrants have been issued at an exercise price of $2.50 per share, which could further bolster the company's capital resources.
Read more →LGVN▼ -24.8%on this newsshared move
Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the Virtual Life Sciences Investor Forum scheduled for June 20, 2024. The presentation will be available for viewing via the company's website, with a replay option for 90 days post-event. Longeveron is actively developing its lead product, Lomecel-B™, aimed at treating conditions such as hypoplastic left heart syndrome and Alzheimer's disease, having received several FDA designations to support its development efforts.
Read more →LGVN▼ -24.8%on this newsshared move
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds MIAMI
Longeveron Inc. announced the exercise of existing warrants worth approximately $4.4 million in gross proceeds. The move involved the purchase of 1,697,891 shares of Class A common stock at an exercise price of $2.35 per share. The funds are intended for the ongoing clinical and regulatory development of their lead product, Lomecel-B, which targets diseases such as HLHS and Alzheimer's. The transaction is expected to close on June 18, 2024, pending customary closing conditions.
Read more →LGVN▼ -22.6%on this news· ran to +201% by day 3
Longeveron Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
Longeveron Inc. announced the successful completion of an investigator meeting for the ELPIS II Phase 2b clinical trial, which is evaluating the efficacy of Lomecel-B™ as a potential treatment for Hypoplastic Left Heart Syndrome (HLHS). The trial aims to address significant survival challenges, as only 50-60% of infants currently survive to adolescence post-treatment. Notably, the Phase 1 trial demonstrated a 100% transplant-free survival rate among infants treated with Lomecel-B™. Enrollment for ELPIS II is expected to conclude by the end of 2024, with participation from several prominent pediatric cardiothoracic institutions.
Read more →LGVNLongeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the Emerging Growth Virtual Conference scheduled for June 12-13, 2024. The presentation is set to take place on June 12 at 1:45 p.m. ET. Investors and attendees can access the webcast through the company's website, where a replay will be available for up to 180 days. Longeveron specializes in regenerative medicines, with its lead product, Lomecel-B™, targeting conditions like hypoplastic left heart syndrome and Alzheimer's disease.
Read more →LGVN▼ -5.5%on this news
Longeveron Announces Contract Development and Manufacturing Business and First Contract
Longeveron Inc. (NASDAQ: LGVN) has launched a new contract development and manufacturing business, signing its first contract with Secretome Therapeutics. This move is expected to generate approximately $4-5 million in annual revenue, leveraging Longeveron's advanced GMP facility. The facility features cleanroom spaces and is equipped to assist other pharmaceutical companies with their development needs. The partnership aims to enhance the portfolio of stem cell-based therapeutics being developed by Secretome Therapeutics.
Read more →LGVNLongeveron to Attend BIO International Convention 2024
Longeveron Inc. (NASDAQ: LGVN) announced its participation in the upcoming BIO International Convention from June 3-6, 2024, in San Diego. The company will discuss potential partnerships related to its Alzheimer's disease program at the event. Lomecel-B™, Longeveron’s leading candidate, has demonstrated positive outcomes in Phase 1 and Phase 2 trials, showing potential in treating Alzheimer’s disease with statistically significant improvements reported. The company aims to connect with industry leaders during the conference to explore future collaborations.
Read more →LGVN▲ +6.9%on this news
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
Longeveron Inc. reported its first quarter financial results for 2024, highlighting ongoing advancements in its clinical trials for Lomecel-BTM in Hypoplastic Left Heart Syndrome and Alzheimer's Disease. The company is on track to complete enrollment in the Phase 2b clinical trial for HLHS by the end of 2024, supported by favorable data from prior trials. Longeveron also raised $11.4 million through equity financing, aimed at funding further clinical development while managing operational costs. However, the company continues to face rising general and administrative expenses amidst a modest increase in revenue.
Read more →LGVN▼ -5.5%on this news· ran to -16% by day 1shared move
Longeveron Announces Board of Directors Planned Transitions Richard Kender, retired SVP of Business Development and Corporate Licensing for Merck & Co., Inc., has been appointed to the Longeveron Board Dr. Roger Hajjar,
Longeveron Inc. has announced significant transitions within its Board of Directors, including the appointment of Richard Kender, a seasoned executive from Merck & Co. Additionally, Dr. Roger Hajjar and Neha Motwani have been nominated to the Board for the upcoming Annual Meeting of Shareholders. These changes aim to enhance the company's governance with experienced leaders as it advances its cellular therapy programs. Current board members Jeffrey Pfeffer and Cathy Ross will not be continuing their terms, creating new opportunities for leadership within the company.
Read more →LGVNLongeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Longeveron Inc. (NASDAQ: LGVN) is set to report its first quarter 2024 financial results on May 14, 2024, following the close of U.S. markets. The announcement also includes details about a conference call and webcast scheduled for later that day. The company, focused on regenerative medicines, will provide a business update during the call. Their leading investigational product, Lomecel-B, has the potential to address various health conditions, including Alzheimer’s disease and age-related frailty.
Read more →LGVNLongeveron to Present at the Planet MicroCap Showcase
Longeveron Inc. (NASDAQ: LGVN) has announced its participation in the Planet MicroCap Showcase scheduled for May 1-2, 2024. During the event, the company will present its advancements in regenerative medicines, specifically its lead investigational product, Lomecel-B™, a therapy derived from young adult donors' bone marrow. This conference offers Longeveron an opportunity to enhance investor relations and discuss its pipeline for conditions like hypoplastic left heart syndrome and Alzheimer’s disease. Interested investors can schedule 1x1 meetings at the conference venue in Las Vegas, NV.
Read more →LGVNLongeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
Longeveron Inc. has successfully raised approximately $11.4 million through a warrant exercise offering and a public offering. This funding is aimed at advancing the company's clinical trial programs for its lead product, Lomecel-B, which targets conditions such as hypoplastic left heart syndrome and Alzheimer's disease. The gross proceeds from the offerings are set to support ongoing clinical and regulatory efforts, as well as other corporate purposes. The company continues its efforts towards obtaining regulatory approvals for its therapies.
Read more →LGVN▼ -40.8%on this newsshared move
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds MIAMI
Longeveron Inc. announced the exercise of its existing warrants, generating $6.2 million in gross proceeds. The funds will help finance ongoing clinical and regulatory development of its lead product, Lomecel-B, targeting conditions such as hypoplastic left heart syndrome and Alzheimer's disease. New warrants for additional stock will also be issued as part of this agreement. The offering is expected to close by April 18, 2024, subject to customary conditions.
Read more →LGVN▲ +73.4%on this news· ran to +109% by day 1shared move
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Longeveron Inc. has announced that its CLEAR MIND Phase 2a clinical trial results of Lomecel-B™ in mild Alzheimer’s disease have been accepted for a featured oral presentation at the 2024 Alzheimer’s Association International Conference. The conference is scheduled to take place from July 28 to August 1, 2024. The acceptance highlights the significance of the study in the context of Alzheimer’s research. In addition to the oral presentation, Longeveron will also present a poster at the conference, showcasing MRI imaging results from the trial.
Read more →LGVN▼ -10.2%on this news· ran to +57% by day 3shared move
Longeveron Announces Closing of $5.2 Million Public Offering
Longeveron Inc. has announced the closure of a public offering that raised approximately $5.2 million for the development of its cellular therapies. This funding aims to support the company's ongoing clinical and regulatory efforts for its lead product, Lomecel-B™, which targets serious conditions like hypoplastic left heart syndrome and Alzheimer’s disease. The offering involved the sale of Class A common stock and warrants, with participation from company insiders, indicating a level of confidence in the company's future. However, the company faces challenges including its history of financial losses and the need for regulatory approvals.
Read more →LGVNLongeveron Announces Pricing of $5.25 Million Public Offering 04/08/2024 MIAMI
Longeveron Inc. has announced a public offering priced at $2.35 per share, aiming to raise approximately $5.25 million. Intended uses for the proceeds include funding clinical and regulatory development of its lead product, Lomecel-B, designated for treating conditions such as Alzheimer's disease and hypoplastic left heart syndrome. The offering is expected to close around April 10, 2024, pending customary closing conditions. Insider participation in the offering reflects a level of confidence among board members.
Read more →LGVNLongeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
Longeveron Inc. CEO Wa'el Hashad presented a letter to shareholders outlining the company's corporate strategy and clinical pipeline for 2024. The focus remains on developing Lomecel-B™ for Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's Disease, with the latter program seeking additional partnerships for funding. Longeveron aims to fully enroll its Phase 2 trial for HLHS by the end of 2024 and is preparing for a potential Biologics License Application (BLA) for the product. Despite promising developments, the company faces financial challenges that necessitate securing additional capital to continue operations effectively.
Read more →LGVNLongeveron Announces 1-for-10 Reverse Stock Split MIAMI, FL
Longeveron Inc. has announced a 1-for-10 reverse stock split, set to take effect on March 26, 2024. This decision aims to raise the trading price of its Class A and Class B common stock to ensure compliance with Nasdaq's minimum bid price requirement. The split, approved by shareholders earlier, will convert every ten existing shares into one, while the total number of authorized shares will remain unchanged. Longeveron is developing regenerative medicines, with its lead product Lomecel-B targeting several serious medical conditions.
Read more →LGVNLongeveron Announces 1-for-10 Reverse Stock Split
Longeveron Inc. has announced a 1-for-10 reverse stock split to take effect on March 26, 2024, as approved by its Board of Directors and stockholders. This action aims to boost the trading price of its common stock for compliance with Nasdaq's minimum bid requirements. The total number of outstanding shares will be significantly reduced, with adjustments made to warrants and equity awards accordingly. Stockholders will not need to take action regarding their shares, as the changes will be made automatically through their brokers or transfer agents.
Read more →LGVN▲ +7.2%on this news
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
Longeveron Inc. reported its 2023 year-end results, focusing on its advancements in Lomecel-B™ for Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's disease. Positive long-term survival data from its ELPIS I trial was shared at the American Heart Association, showing promising outcomes for children treated with Lomecel-B™. However, the company faced a significant drop in revenues and has decided to discontinue its Aging-related Frailty program in Japan to prioritize its HLHS research. Longeveron plans to complete enrollment for its ELPIS II trial in 2024 and has secured $6.4 million in equity financing to support these efforts.
Read more →LGVNLongeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
Longeveron Inc. has announced that it will report its financial results for the year 2023 on February 27, 2024, after market close. The report will be followed by a conference call at 5 PM ET to discuss the results and provide a corporate update. The company's lead investigational product, Lomecel-B™, is under development for several indications, including hypoplastic left heart syndrome and Alzheimer's Disease, demonstrating its diverse therapeutic potential.
Read more →LGVN▼ -16.1%on this news· ran to -36% by day 3
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
Longeveron Inc. announced a significant patent allowance from the U.S. Patent and Trademark Office for its lead investigational product, Lomecel-B, which utilizes Medicinal Signaling Cells to enhance immune responses in aging-related frailty patients. This patent expands upon prior patents granted in the European Union and Japan, where a Phase 2 trial is in progress. The technology is particularly relevant for patients receiving vaccines for conditions like COVID-19. Promising early trial results for Lomecel-B relate to its safety and effectiveness in cognitive function, alongside ongoing investigations for additional indications involving serious health conditions.
Read more →LGVN▲ +7.2%on this news
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. has announced the successful closing of a registered direct offering amounting to approximately $2.36 million. This offering included the sale of over 1.3 million shares of common stock priced at $1.745 per share, alongside unregistered warrants. The company intends to utilize the net proceeds for working capital and various corporate purposes. The scope of Longeveron’s research focuses on innovative cellular therapies for serious health conditions related to aging.
Read more →LGVN▼ -22.8%on this newsshared move
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. has announced a $2.36 million registered direct offering, selling 1,355,301 shares at $1.62 each under Nasdaq rules. The funds are intended for working capital and corporate purposes. Additionally, the company will issue warrants in a concurrent private placement. The offering is expected to close around December 26, 2023, pending customary closing conditions.
Read more →LGVN▼ -22.8%on this newsshared move
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. announced a registered direct offering, raising approximately $2.36 million by selling 1,355,301 shares of common stock at a price of $1.745 each, expected to close on December 22, 2023. The offering is aimed at providing working capital and general corporate purposes. In conjunction with the offering, unregistered warrants have also been issued, which can be exercised at $1.62 per share. The proceeds from this offering will aid Longeveron in advancing its clinical stage development of cellular therapies.
Read more →LGVN▼ -16.9%on this news· ran to -36% by day 1shared move
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
Longeveron Inc. announced new positive clinical data from its CLEAR MIND Phase 2a trial, showing that its investigational product, Lomecel-B™, improved cognitive function in patients with mild Alzheimer’s disease. The expanded results confirmed earlier findings on safety and showcased significant reductions in neuroinflammation and brain volume loss based on MRI analyses. Caregiver reports highlighted improvements in quality of life among treated patients. The company plans to present these promising findings at a major medical meeting in 2024, reinforcing the therapeutic potential of Lomecel-B.
Read more →LGVN▼ -5.7%on this news
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
Longeveron reported promising third-quarter results, emphasizing positive top-line findings from their CLEAR MIND trial, which demonstrated the safety and potential efficacy of Lomecel-B in treating mild Alzheimer’s disease. Furthermore, long-term survival data from the ELPIS I trial for patients with hypoplastic left heart syndrome will be presented at the American Heart Association meeting, showcasing a 100% survival rate at five years post-treatment. The company has secured $4 million in equity financing to support its clinical programs, despite facing a decline in grant revenue and rising administrative costs.
Read more →LGVNLongeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
Longeveron Inc. (NASDAQ: LGVN) is set to report its third quarter 2023 financial results on November 10, 2023, and will discuss these results along with updates on its clinical programs during a conference call. The company is notably developing its lead product, Lomecel-B, which has applications in treating conditions like Alzheimer's disease and Aging-related Frailty. This event will include a question-and-answer session, providing an opportunity for investors to engage with the company on its future prospects.
Read more →LGVNLongeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
Longeveron Inc. announced positive top-line results from its Phase 2a clinical trial of Lomecel-B™ for treating mild Alzheimer’s disease. The trial met its primary safety endpoint, with no significant safety issues reported, and the results suggest a promising safety profile and potential therapeutic benefits. CEO Wa'el Hashad highlighted the importance of these findings for future clinical trials, especially with upcoming biomarker data expected soon. The company is also progressing in other indications, including aging-related frailty and hypoplastic left heart syndrome.
Read more →LGVNLongeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Longeveron Inc. has announced the closing of a $4 million registered direct offering of its Class A common stock. The offering, priced at $1.65 per share, allows the company to raise funds aimed at supporting the clinical development of its therapeutic product, Lomecel-B™, among other corporate purposes. Additionally, the company issued unregistered Series A and Series B warrants in a concurrent private placement. The successful completion of this offering reflects investor confidence in Longeveron's clinical objectives.
Read more →LGVN▼ -9.2%on this newsshared move
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MIAMI
Longeveron Inc. announced a registered direct offering of $4 million priced at $1.65 per share, which includes unregistered Series A and B warrants. The offering is facilitated by H.C. Wainwright & Co. and is set to close on October 13, 2023. Proceeds will fund ongoing clinical trials of Lomecel-B, aimed at addressing chronic aging-related conditions like Alzheimer's disease. The company is leveraging a 'shelf' registration statement to conduct this offering under Nasdaq rules.
Read more →LGVN▼ -16.7%on this news· ran to -34% by day 3
Longeveron Announces Positive Top-Line Results for Lomecel-B TM in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease Company to Hold Conference Call & Webcast Today, October 5 at 8:00am
Longeveron Inc. announced positive top-line results from its Phase 2a CLEAR MIND clinical trial for Lomecel-B in treating mild Alzheimer's disease. The trial showed promising safety data, with no significant adverse events reported. Key endpoints were met, including consistent efficacy observations when compared to earlier studies. The company plans to release additional biomarker data later this month, hoping to further characterize Lomecel-B's clinical effects.
Read more →LGVNLongeveron Issues Letter to Stockholders
Longeveron Inc. issued a letter to stockholders updating them on the progress of its lead product, Lomecel-B™, which is under investigation for treating conditions like Hypoplastic Left Heart Syndrome and Alzheimer's disease. CEO Wa’el Hashad highlighted advances in clinical trials, including a 100% survival rate in HLHS patients and ongoing Phase 2 trials for Alzheimer's, while introducing new leadership to support the company's objectives. A $30 million rights offering is underway to fund these initiatives and bolster shareholder value.
Read more →LGVNLongeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
Longeveron Inc., a biotechnology company focused on developing cellular therapies, is set to present at the 25th Annual H.C. Wainwright Global Investment Conference from September 11-13, 2023. The CEO will deliver a pre-recorded presentation on the company's cellular therapy programs, while the CFO will discuss clinical trial progress and investment strategies in person. Additionally, there is an ongoing rights offering that allows stockholders to purchase shares at a subscription price of $3.00 each, enhancing investor opportunities.
Read more →LGVNLongeveron to Participate in the 149th Annual National Investment Banking Association Conference
Longeveron Inc. announced its participation in the 149th Annual National Investment Banking Association Conference, scheduled for September 6-7, 2023. CEO Wa'el Hashad will present the company's cellular therapy programs, while the executive team will engage in discussions about clinical trial progress and investment strategies. The company is currently conducting a rights offering to raise capital, allowing stockholders to purchase additional shares at $3.00 each, amplifying its funding efforts for ongoing research and development. Longeveron's lead investigational product, Lomecel-B™, addresses various aging-related conditions and is undergoing clinical trials for several indications.
Read more →LGVN▲ +8.2%on this news
Longeveron Rights Offering Subscription Period Begins
Longeveron Inc. has commenced the subscription period for a previously announced rights offering, priced at $3.00 per share. This offering is designed for existing shareholders, ending on September 21, 2023, unless extended. The company has appointed R.F. Lafferty & Co., Inc. as the dealer-manager for this offering. Additionally, Longeveron retains the right to modify or cancel the offering at its discretion, which introduces a level of uncertainty for potential investors.
Read more →LGVNLongeveron Rights Offering Declared Effective and Calendar Finalized MIAMI
Longeveron Inc. announced the effectiveness of its rights offering, allowing shareholders to purchase additional shares at a set price. The offering will include five tradable subscription rights per share of common stock, accompanied by an over-subscription privilege. Important dates for the offering have been established, enhancing shareholder participation opportunities. The company aims to leverage this offering to further its clinical development of cellular therapies for severe aging-related conditions.
Read more →LGVN▼ -7%on this newsshared move
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
Longeveron Inc. is hosting a virtual Key Opinion Leader event on August 16, 2023, focusing on Medicinal Signaling Cells (MSCs) for treating Hypoplastic Left Heart Syndrome (HLHS) using Lomecel-B™. Esteemed experts will discuss the existing treatment landscape and the potential impact of MSCs on patient outcomes. Additionally, company leaders will provide updates on the ongoing Phase 2 ELPIS II trial and insights into future directions for the ongoing development of Lomecel-B™. This event highlights Longeveron’s commitment to developing regenerative therapies for unmet medical needs.
Read more →LGVN▼ -7%on this newsshared move
Longeveron Announces Pricing for Rights Offering and Expected Calendar MIAMI
Longeveron Inc. announced a rights offering for its Class A common stock, allowing shareholders the opportunity to purchase additional shares at $3.00 each. The subscription rights will be made available to stockholders of record on August 16, 2023, with the offering expected to span into late September. This initiative is intended to bolster Longeveron's financial capabilities as it advances its clinical programs, including therapies for conditions like Alzheimer's disease. The company also outlined specific dates regarding the ownership, trading, and expiration of the rights offering.
Read more →LGVNLongeveron Reports Second Quarter 2023 Results and Provides Corporate Update
Longeveron Inc. reported positive progress in its clinical trials, achieving over 50% enrollment in the ELPIS II Phase 2 trial for hypoplastic left heart syndrome. The company also anticipates sharing top-line results for its CLEAR MIND Alzheimer's trial by October 2023. Despite these advancements, Longeveron experienced a revenue decline of 41% year-over-year and increased general and administrative expenses, highlighting some financial challenges. Additionally, they have strengthened their leadership team with the appointment of new executives.
Read more →LGVNLongeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
Longeveron Inc. has announced that the Phase 2 ELPIS II study of its cell therapy product Lomecel-B™ for treating Hypoplastic Left Heart Syndrome (HLHS) has exceeded the 50% enrollment milestone. To accelerate enrollment completion, the company has activated an additional clinical site beyond the initial seven planned. The trial is funded by the National Heart, Lung, and Blood Institute and aims to evaluate the safety and efficacy of Lomecel-B™ in infants undergoing cardiac surgery. A webinar is scheduled to discuss the potential of Lomecel-B™ in improving outcomes for HLHS patients.
Read more →LGVNLongeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
Longeveron Inc. announced that it will report its second quarter 2023 financial results on August 11, 2023, before the market opens. A conference call and webcast will follow to discuss these results and provide updates on the company's clinical programs. The company is focused on developing cellular therapies for chronic aging-related conditions using its investigational product Lomecel-B™.
Read more →LGVNLongeveron Appoints Lisa Locklear as Chief Financial Officer MIAMI, FL
Longeveron Inc. has appointed Lisa Locklear as Executive Vice President and Chief Financial Officer, effective July 31, 2023. Locklear brings extensive experience in finance and leadership from major companies such as Avanir Pharmaceuticals. She aims to strengthen the financial foundation of Longeveron, particularly in advancing their cellular therapy product, Lomecel-B. This appointment reflects Longeveron's focus on innovation in treating serious conditions associated with aging and chronic diseases.
Read more →LGVNLongeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
Longeveron Inc. has appointed Dr. Nataliya Agafonova as Chief Medical Officer, effective July 1, 2023. Dr. Agafonova comes with significant experience in drug development, having held senior positions at notable pharmaceutical companies like Otsuka and Bristol-Myers Squibb. In her role, she will oversee Longeveron's global clinical development and regulatory strategy, particularly for the company's investigational product Lomecel-B™, which is being developed for conditions such as hypoplastic left heart syndrome and Alzheimer's Disease.
Read more →LGVNLongeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
Longeveron Inc. announced that its Chairman and Co-founder, Dr. Joshua Hare, has been inducted as a fellow of the National Academy of Inventors. This honor recognizes his significant contributions to the development of stem cell therapies targeting heart disease. The company emphasizes the potential of its lead therapeutic candidate, Lomecel-B™, in addressing serious medical needs due to the shortage of heart transplant donors. The induction reflects both Dr. Hare's innovative work and strengthens Longeveron's position in the biotech industry.
Read more →LGVN▼ -5.9%on this news
Longeveron Files Registration Statement for Rights Offering
Longeveron Inc. has filed a registration statement with the SEC for a rights offering aimed at raising up to $30 million. Shareholders and warrant holders will receive tradable subscription rights to purchase common stock at a price yet to be determined. The offering is part of Longeveron’s strategy to fund ongoing clinical trials of its lead product, Lomecel-B, which targets serious age-related conditions. The registration is pending effectiveness, and several risks could impact the success of the offering.
Read more →LGVNCell - Based Therapies A Regenerative Medicine Company May 2023 2 Forward Looking Statements Certain statements in this press release that are not historical facts are forward - looking statements made pursuant to the sa
Longeveron, known for its cell-based therapies, is actively pursuing advancements in regenerative treatments, particularly through its product Lomecel-B. This therapy targets significant unmet medical needs, including Hypoplastic Left Heart Syndrome and Alzheimer's disease. Despite holding promising FDA designations, the company's future performance is uncertain and may be influenced by regulatory decisions and its ability to secure additional funding. The ongoing clinical trials aim to demonstrate the efficacy and safety of Lomecel-B in treating critical health conditions.
Read more →LGVNLongeveron Welcomes Three New Prominent Board Members
Longeveron Inc. has announced the election of three new board members at their Annual Meeting of Stockholders, held on June 9, 2023. The new directors, Khoso Baluch, Jeffrey Pfeffer, and Wa'el Hashad, are expected to provide valuable expertise as the company advances its regenerative medicine initiatives. With Hashad recently appointed as CEO, there is heightened optimism about the development of Lomecel-B™, the company’s lead investigational product. The outgoing directors were acknowledged for their contributions to the company’s progress.
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results -- New long-term survival data disclosed from ELPIS I trial of Lomecel-B TM for Hypoplastic Left Heart Syndrome; Data reinforce p
Longeveron Inc. recently provided a corporate update alongside its financial results for the first quarter of 2023. Highlights include new long-term survival data from the ELPIS I trial of Lomecel-B, indicating a 100% survival rate for infants with Hypoplastic Left Heart Syndrome. The company also initiated a Phase 2 clinical trial for Lomecel-B in Aging-Related Frailty in Japan. However, financial results show an increase in net loss to $4.6 million and a decline in total revenues, signaling ongoing challenges despite progress in their clinical programs.
Read more →LGVN▲ +26.6%on this newsshared move
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
Longeveron announced promising long-term survival data from its ELPIS I trial, showing a 100% survival rate for children treated with Lomecel-B™ for hypoplastic left heart syndrome (HLHS) up to 5 years of age. This outcome significantly surpasses the historical 20% mortality rate for HLHS patients. The company is currently enrolling participants for the Phase 2a ELPIS II trial to further investigate Lomecel-B™'s efficacy. With regulatory designations supporting its use, Lomecel-B™ has the potential to transform the treatment landscape for HLHS.
Read more →LGVNLongeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
Longeveron Inc. has announced the date for its first quarter 2023 financial results, set to be released before the U.S. financial markets open on May 12, 2023. A conference call will be hosted by management on the same day at 8:30 a.m. ET to discuss the financial results and provide a corporate update. The company is known for its regenerative medicine development, particularly its lead product, Lomecel-B™, which targets several medical conditions including Alzheimer’s Disease.
Read more →LGVNLongeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
Longeveron Inc. has commenced its Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty, marking the first patient dosed in Japan. The trial, which aims to enroll 45 patients, will primarily evaluate the safety of Lomecel-B™ while assessing its efficacy in the elderly population. This study aligns with the company's previous findings in the U.S. that showed significant improvement in patients' walking distance. With Japan facing a substantial aging population, the trial seeks to address notable unmet medical needs.
Read more →LGVN▼ -11.5%on this news
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results -- Full results from ELPIS I trial published in European Heart Journal Open - -- First patient to be randomized in
Longeveron Inc. provided a corporate update, announcing progress in its clinical trials and reporting financial results for the fourth quarter and full year 2022. The company's pivotal ELPIS I trial data was published in the European Heart Journal Open. Despite challenges such as reduced revenue and increased net losses, Longeveron remains optimistic, emphasizing advancements in its product Lomecel-BTM. They anticipate sufficient funds to maintain operations through the first half of 2024.
Read more →LGVNLongeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
Longeveron Inc. has announced that it will release its financial results for the fourth quarter and full year of 2022 on March 10, 2023. The announcement includes a scheduled conference call to discuss these results and updates about the company. Longeveron is known for its development of regenerative medicines, particularly its lead therapy Lomecel-B™, which is currently undergoing clinical trials for multiple indications. The conference call will take place before the U.S. markets open on the specified date.
Read more →LGVNLongeveron Appoints Wa'el Hashad as Chief Executive Officer Hashad is a former executive at Avanir, Amgen, Boehringer Ingelheim, Eli Lilly, and early-stage biotechnology companies Global leader brings over 35 years of ex
Longeveron Inc. has appointed Wa'el Hashad as its new Chief Executive Officer, effective March 1, 2023. Hashad, who previously held executive roles at companies like Avanir and Amgen, brings extensive experience in drug development and commercialization. His leadership is expected to guide the company through key milestones in their clinical programs focused on regenerative medicines for conditions like Alzheimer's Disease and hypoplastic left heart syndrome. Current Interim CEO Chris Min will continue in the role of Chief Medical Officer.
Read more →LGVNLongeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
Longeveron announced the publication of final data from the ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome in the European Heart Journal Open. The study successfully met its primary safety endpoint, with all participants remaining alive and transplant-free one year post-treatment. Notably, there were indications of potential cardiac function improvement among treated infants. The company is advancing the ongoing evaluation of Lomecel-BTM through a Phase 2a clinical trial.
Read more →LGVN▲ +9.5%on this news
Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones - Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B for Aging-Related Frailty in Japan in 1Q23
Longeveron Inc. has provided a corporate update outlining its strategic priorities for 2023, including the expectation to enroll the first patient in its Phase 2 clinical trial of Lomecel-B for Aging-Related Frailty in Japan in the first quarter. The company has made substantial progress with its lead product, Lomecel-B, targeting several medical indications such as Hypoplastic Left Heart Syndrome and Alzheimer's Disease. Additionally, Longeveron has successfully extended its cash runway, enhancing its ability to execute on its pipeline and milestones for the year.
Read more →LGVN▼ -9.2%on this news
Longeveron to Participate in Upcoming 2022 Investor Conferences
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming invest
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results -- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results -- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron's Phase 2a trial for Alzheimer's -Conference call sched
Read more →LGVN▲ +15.9%on this newsshared move
Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease
MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-BTM
Read more →LGVNLongeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022
MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial re
Read more →LGVNLongeveron to Present at the Annual Dawson James Small Cap Growth Conference
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and
Read more →LGVNLongeveron Names Jerome Bailey Vice President of Business Operations
MIAMI, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations. He jo
Read more →LGVNLongeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference
MIAMI, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that Chris Min, M.D., Ph.D., Inter
Read more →LGVN▼ -7.8%on this newsshared move
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants New designation may expedite FDA review and pote
Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants designation may expedite FDA review and potential approval to address this life-threatening heart condition aff
Read more →LGVNLongeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
MIAMI, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that the European Patent Office (EPO) has issued a notice of i
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices Agency Accepts Amended Aging Frailty study design August 8, 2022, allowing the trial to begin
Read more →LGVNLongeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022
MIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its s
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results -Longeveron's Phase 2a trial of Lomecel-B for patients with mild Alzheimer's Disease proceeding on schedule, currently at 50% en
Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results -Longeveron's Phase 2a trial of Lomecel-B for patients with mild Alzheimer's Disease proceeding on schedule, currently at 50% enrollment Japanese Pharmaceuticals and Medical Devices Agency Accepts
Read more →LGVN▲ +21.2%on this news
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheime
Read more →LGVN▲ +10.8%on this news
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results -Conference call scheduled for 8:30 a.m. ET today- Miami, Florida
Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results -Conference call scheduled for 8:30 a.m. ET today- Florida - May 13, 2022- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular the
Read more →LGVNLongeveron to Announce First Quarter 2022 Financial Results on May 13, 2022
MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fi
Read more →LGVNLongeveron Announces CEO Transition
-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "
Read more →LGVNLongeveron Announces CEO Transition -Geoff Green stepping down as CEO, effective
Longeveron Announces CEO Transition -Geoff Green stepping down as CEO, effective -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent Miami, FL - May 9, 2022 - Longeveron Inc. (NASDAQ: LGVN) ("Longever
Read more →LGVN▲ +5%on this news· ran to +25% by day 3
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today its Chief Science Officer, Co-Fou
Read more →LGVN▼ -6.4%on this newsshared move
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
MIAMI, April 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Develo
Read more →LGVN▼ -9.7%on this news· ran to -26% by day 3
Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer Dr. Min will lead global clinical development and regulatory strategy Miami, Florida
Expands Executive Leadership Team; Appoints Chris Min, M.D., Ph.D. as Chief Medical Officer Min will lead global clinical development and regulatory strategy Florida - April 05, 2022 - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology
Read more →LGVN▲ +105.4%on this news· ran to +132% by day 1shared move
Longeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association
Results Support Further Exploration of Therapeutic Potential of Lomecel-B to Slow Cognitive Decline, Improve Quality of Life for Alzheimer’s Patients Phase 2 Trial Recently Launched With First Patient Treated MIAMI, March 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LG
Read more →LGVN▲ +9.2%on this news
Longeveron Presents at Second Euro-Geroscience Conference
MIAMI, March 24, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management presented at the
Read more →LGVNLongeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
MIAMI, March 15, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive
Read more →LGVNLongeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Currently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a
Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimer's Disease and Covid-related Acute Respiratory Distress Syndrome
Read more →LGVN▼ -8.9%on this news
Longeveron to Announce Fourth Quarter and Full Year 2021 Financial Results, on March 11, 2022
MIAMI, March 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its
Read more →LGVNLongeveron to Present at Q1 Virtual Investor Summit Conference
MIAMI, March 02, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive
Read more →LGVN▼ -7.3%on this news
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors Girolamo brings legal, finance and M&A experience to cell therapy company Miami, Florida - February 17 th , 2022 - Longeveron Inc. (NASDA
Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors Girolamo brings legal, finance and M&A experience to cell therapy company February 17th, 2022 - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developi
Read more →LGVN▲ +5.5%on this news· ran to +19% by day 1
Longeveron to Participate in Phacilitate Advanced Therapies Week
MIAMI, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will be speaking a
Read more →LGVN▼ -10.2%on this news
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the desi
Read more →LGVNNasdaq: LGVN www.longeveron.com H.C. Wainwright BioConnect 2022 Virtual Conference Cell Therapy for Aging - Related Disease & Life - Threatening Conditions Forward Looking Statements 2 Certain statements in this presenta
Nasdaq: LGVN www.longeveron.com H.C. Wainwright BioConnect 2022 Virtual Conference Cell Therapy for Aging - Related Disease & Life - Threatening Conditions Forward Looking Statements 2 Certain statements in this presentation that are not historical facts are forward - looking st
Read more →LGVNLongeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
MIAMI, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its P
Read more →LGVNLongeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference
MIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive
Read more →LGVNLongeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS) HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per
Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS) Miami, Florida-December 6, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular
Read more →LGVN▲ +11.8%on this newsshared move
Longeveron Inc. Announces Closing of a $20.5 Million Private Placement
MIAMI, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the closing of its previously annou
Read more →LGVN▼ -22.2%on this newsshared move
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement Miami, Florida
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement Miami, Florida-December 1, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threaten
Read more →LGVNLongeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients
MIAMI, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that it has entered int
Read more →LGVN▲ +135.3%on this news· ran to +490% by day 3
U.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrom
Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Infant Heart Condition Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year Miami, Florida-November 18th, 2021- L
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results -- Longeveron to hold conference call today at 8:30 AM EDT Miami, Florida - November 12 th , 2021- Longeveron Inc. (NASDAQ: LGVN)
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results -- Longeveron to hold conference call today Miami, Florida - November 12th, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company dev
Read more →LGVNLongeveron to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 12, 2021
MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its t
Read more →LGVN▼ -8.5%on this newsshared move
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Bior
Read more →LGVNLongeveron Announces Activation of Two New Clinical Sites in ELPIS II Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today the activation of two new clinical
Read more →LGVNLONGEVERON INC. (NASDAQ: LGVN) CLASS ACTION LAWSUIT FILING DEADLINE REMINDER: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc.
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of
Read more →LGVN▲ +7.6%on this newsshared move
Longeveron to Present at the 2021 Dawson James Securities 6th Annual Small Cap Growth Conference
MIAMI, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive
Read more →LGVNLONGEVERON INC. (NASDAQ: LGVN) INVESTOR CLASS ACTION FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc.
NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of
Read more →LGVNNasdaq: LGVN October 2021 Cell Therapy for Aging - Related Disease & Life - Threatening Conditions Forward Looking Statements 2 Certain statements in this presentation that are not historical facts are forward - looking
Nasdaq: LGVN October 2021 Cell Therapy for Aging - Related Disease & Life - Threatening Conditions Forward Looking Statements 2 Certain statements in this presentation that are not historical facts are forward - looking statements that reflect management's current expectations,
Read more →LGVNTrial Results: Lomecel - B for Aging Frailty A Phase 2b, Randomized, Blinded and Placebo - Controlled Trial to Evaluate the Safety and Efficacy of Lomecel - B Infusion in Patients with Aging Frailty Jorge G. Ruiz, MD, FA
Trial Results: Lomecel - B for Aging Frailty A Phase 2b, Randomized, Blinded and Placebo - Controlled Trial to Evaluate the Safety and Efficacy of Lomecel - B Infusion in Patients with Aging Frailty Jorge G. Ruiz, MD, FACP Veterans' Successful Aging for Frail Elders (VSAFE) Assoc
Read more →LGVNLongeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity
Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270 Oral presentation today at the International Conference for Frailty & Sarcopenia Research MIAMI, Sept. 29, 2021
Read more →LGVNLongeveron Announces Multiple Presentations at the 11th Annual International Conference on Frailty & Sarcopenia Research
MIAMI, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related, and life-threatening conditions, today announced that the Company’s Lomecel-B res
Read more →LGVNLongeveron Announces Dr. Jorge Ruiz as Speaker for Roundtable Discussion & Presentation at 2021 International Conference for Frailty & Sarcopenia Research
-- Jorge Ruiz, M.D., Associate Director for Clinical Affairs, Geriatric Research at the Miami VA Healthcare System, will present Longeveron’s Aging Frailty Phase 2b Trial Data -- National Institute on Aging-funded study showed significant, dose-dependent improvement in walking d
Read more →LGVNLONGEVERON INC. (NASDAQ: LGVN) FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against the Longeveron Inc.
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf o
Read more →LGVNLongeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell Therapy
MIAMI, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing its proprietary product, Lomecel-B, and other cellular therapies for chronic aging-related and life-threatening conditions, has
Read more →LGVN▲ +7.4%on this newsshared move
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients. --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any trea
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients. --Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-trea
Read more →LGVNLongeveron to Present at H.C. Wainwright 23rd Annual Global Investor Conference
MIAMI, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that management will present virt
Read more →LGVN▼ -27.9%on this news
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty -- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (
Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) Longeveron to hold conference call today at 8:00 AM EDT FL - Aug
Read more →LGVN▼ -27.9%on this news
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results -- Longeveron to hold conference call today at 8:00 AM EDT Miami, Florida
Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results Longeveron to hold conference call today at 8:00 AM EDT Florida - August 13, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cel
Read more →LGVNLongeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021
MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its s
Read more →LGVNLongeveron Announces First Patient Treated in Phase 2b Hypoplastic Left Heart Syndrome (HLHS) Clinical Study
• Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS • Funded by the National Heart, Lung and Blood Institute (Grant number 1UG3HL148318 and 1U24HL148316) in collaboration with Longever
Read more →LGVNLongeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific Meeting
MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B,
Read more →LGVNLongeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer’s Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International Conference
MIAMI, June 24, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion
Read more →LGVNLongeveron to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Cell Summit
MIAMI, June 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Executive
Read more →LGVNLongeveron’s Chairman and Chief Science Officer Invited by National Academy of Medicine to Speak at Longevity Symposium
MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that its Co-founder and Chairman,
Read more →LGVNLongeveron Announces the Appointment of Ursula Ungaro to its Board of Directors Miami, Florida - May 25 th , 2021 - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company devel
Announces the Appointment of Ursula Ungaro to its Board of Directors Miami, Florida - May 25th, 2021 - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threateni
Read more →LGVNLongeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs
MIAMI, May 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as S
Read more →LGVNLongeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results Miami, Florida - May 14 th , 2021- Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology compa
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial Results Miami, Florida - May 14th, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-relat
Read more →LGVNSenior Scientist Anthon y Oliva , PhD Director of Patient & Clinical Services Jessic a Protenic , B.S.N. , R.N. International E x ecutive Director P a u l T . L e h r , J . D . Associate Directo r , Medical A f airs K ev
Senior Scientist Anthon y Oliva , PhD Director of Patient & Clinical Services Jessic a Protenic , B.S.N. , R.N. International E x ecutive Director P a u l T . L e h r , J . D . Associate Directo r , Medical A f airs K ev i n N . R a m d a s , M . D . , M . P . H . May 2021 Lon g
Read more →LGVNLongeveron to Release First Quarter 2021 Financial Results and Hold Conference Call on May 14, 2021
MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fi
Read more →LGVNLongeveron Invited to Present at the Benzinga Global Small Cap Conference
Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of Lomecel-B infusion in Aging Frailty subjects. Top-line results from the Aging Frailty
Read more →LGVNLongeveron Selected to Present at the 2021 World Stem Cell Summit
MIAMI, April 27, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the
Read more →LGVNLongeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Vaccination Study intended to evaluate safety, and po
Longeveron Announces Successful Completion of Phase I/II Clinical Study of Lomecel-B Infusion in Aging Frailty Subjects to Improve Immune Response Following Influenza Study intended to evaluate safety, and potential immunomodulatory effect of Lomecel-B on aging-associated decl
Read more →LGVNLongeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B compar
Read more →LGVNLONGEVERON Cell-Based Therapies Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease Study meets primary safety endpoint; positive secondary efficacy assessmen
Cell-Based Therapies Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive f
Read more →LGVNLongeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Miami, Florida
Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results Miami, Florida-March 30, 2021- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related
Read more →LGVNLongeveron Schedules 2020 Fiscal Year End Business Update Conference Call
MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced it will host a conference call at
Read more →LGVNLongeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that Geoff Gree
Read more →LGVNLongeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering MIAMI, FLORIDA
Announces Partial Exercise of Over-Allotment Option in Initial Public Offering MIAMI, FLORIDA - March 15, 2021 -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and l
Read more →LGVNLongeveron’s Lomecel-B™ Approved by FDA for Compassionate Use for the Treatment of Child with Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, March 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food & Drug Administ
Read more →LGVNLongeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations Agreement Provides Additional Intellectual Property and Clinical Data for Longeveron While S
University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations Additional Intellectual Property and Clinical Data for Longeveron While Strengthening Research and Development Relationship Miami, Florida-March 10, 2021- Longevero
Read more →LGVNLongeveron Expands Enrollment Criteria for its Phase 1 RECOVER Trial Evaluating Lomecel-B Infusion to Treat Acute Respiratory Distress Syndrome due to COVID-19 or Influenza Infection
MIAMI, March 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that enrollment criteria for its P
Read more →LGVNLongeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
Trial funded in part by a National Institute on Aging Small Business Innovation Research (SBIR) Grant Trial objectives include evaluation of Lomecel-B’s effect on physical function, mobility, strength, balance, endurance, fear and risk of falling, inflammatory biomarkers and cli
Read more →LGVNLongeveron Announces Successful Completion of Phase 1 Clinical Study of Lomecel-B Intramyocardial Injection in Hypoplastic Left Heart Syndrome Patients
Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported Full results of the Phase 1 clinical trial expected to be released in Q2 2021 Phase 2 trial expected to commence in Q3 2021 MIAMI, F
Read more →LGVNLongeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate Finance Executives to the Board of Directors
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo
Read more →LGVNLongeveron Inc. Announces Pricing of an Upsized $26.6 Million Initial Public Offering and Nasdaq Listing
MIAMI, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the pricing of an underwritten initi
Read more →Competitive Position
How LGVN ranks across every disease it competes inCompetitive Position is a premium feature
See how LGVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial